Anti-abortion advocates across the nation are expressing mounting impatience with the Trump administration’s handling of abortion pill regulations, seeking swifter action to limit online prescriptions they believe are weakening state-level abortion prohibitions.
This week’s federal court decision in Louisiana highlighted growing tensions over the issue. U.S. District Judge David Joseph, a Trump appointee, indicated the state presented compelling arguments while choosing not to immediately halt telehealth prescriptions for the abortion medication mifepristone.
Organizations opposing abortion are urging the Food and Drug Administration to expedite its ongoing review, hoping for new limitations on mifepristone access, particularly through online medical consultations. Federal officials maintain that comprehensive reviews require adequate time.
These advocacy groups have concentrated their pressure primarily on the FDA rather than directly criticizing the Republican president, whose three Supreme Court nominees helped enable the 2022 decision that eliminated Roe v. Wade protections and permitted current state prohibitions. However, the administration’s court filings requesting delays until completing its review have angered some activists.
“The stall tactics are beyond frustrating,” said Kristi Hamrick, speaking for Students for Life of America. Hamrick suggested the administration could also prevent pill distribution through mail by reinterpreting and enforcing a 19th-century statute.
Judge Joseph delivered a split decision Tuesday in litigation initiated by Louisiana Attorney General Liz Murrill alongside a woman claiming her partner forced her to use mifepristone to terminate her pregnancy.
The broader objective involves reversing FDA policies that have expanded pill accessibility. Murrill and officials from other states filing comparable lawsuits argue that online medication availability undermines prohibition effectiveness in the 13 states banning abortion throughout pregnancy, with narrow exceptions.
Provider surveys indicate telehealth availability helps explain why U.S. abortion numbers haven’t declined following Roe’s reversal. Although state bans include medication abortion restrictions, some Democratic-led states have enacted protective legislation for healthcare providers prescribing pills via telehealth and mailing them to ban states. These protective statutes face testing through various legal proceedings.
In Louisiana’s case, Joseph rejected Murrill’s request for immediate telehealth prescription blocking during ongoing litigation. However, he indicated eventual action remains possible and plaintiffs would likely prevail because the state demonstrated “irreparable harm.”
The judge also mandated FDA reporting on its drug review progress within six months.
Wednesday brought Murrill’s appeal filing to the U.S. 5th Circuit Court of Appeals, seeking accelerated action.
Family Research Council President Tony Perkins, an influential conservative voice and former Louisiana legislator, praised Murrill’s appeal.
Perkins noted public surprise upon learning abortion numbers haven’t decreased since the 2022 Supreme Court ruling.
“Bewilderment sets in,” he explained. “We’re already seeing an enthusiasm gap between the parties. What the Republicans do not need is a dampening of enthusiasm in their base.”
He hopes the administration will impose pill restrictions rather than risk losing conservative, anti-abortion voter support in November’s elections.
Some organizations adopt more cautious approaches.
National Right to Life’s federal affairs director Madison LaClare expressed confidence in the administration’s mifepristone review process. SBA Pro-Life America president Marjorie Dannenfelser avoided presidential criticism, stating: “The Trump-Vance administration has an important opportunity right now to prioritize women’s safety.”
Nevertheless, recent voting patterns suggest abortion-rights supporters maintain political advantage. Since Roe’s overturn, abortion questions have appeared on ballots in 17 states, with abortion-rights positions winning in 14 instances.
“There seems to be an emerging consensus in the country that people don’t want to ban abortion,” observed Rachel Rebouche, a University of Texas School of Law professor studying abortion issues.
Wednesday’s FDA statement to The Associated Press confirmed ongoing mifepristone safety evaluation, “including the collection of robust and timely data, evaluation of data integrity, and implementation of the analyses, validation, and peer-review.”
Following completion, the agency will determine whether prescription rule modifications are warranted.
The FDA noted such academic studies typically require over a year but the agency aims for faster completion. Spokespersons declined specifying when work commenced.
Mifepristone has remained a key focus for anti-abortion activists and congressional allies since Trump’s return to office. During January 2025 confirmation proceedings, Health and Human Services Secretary Robert F. Kennedy Jr. faced repeated Republican questioning about the medication and confirmed presidential safety review requests.
Frustration over perceived FDA inaction intensified last fall when the agency approved an additional generic mifepristone version.
The medication typically combines with another drug, misoprostol, for abortion procedures.
Originally approved in 2000 as safe and effective for early pregnancy termination, mifepristone initially carried strict prescribing and distribution limitations due to rare excessive bleeding cases. Only specially certified physicians could prescribe it, requiring in-person appointments for pill dispensing.
Both requirements ended during COVID-19. FDA officials explained that over 20 years of monitoring and reviewing numerous studies involving thousands of women demonstrated safe unsupervised usage.
